Keyword: Geoffrey Porges

With the aducanumab flop, shareholders are questioning management’s strategy—and an uncertain pipeline isn’t helping, either.

Celgene’s Revlimid may have slipped in previously untreated follicular lymphoma. But in the second-line setting, the drug has a win.

Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.

Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.

Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.

Pfizer just got some backup on its quest to snag a nod for ulcerative colitis med Xeljanz. On Thursday, an FDA AdComm voted to approve the drug.

AbbVie may not seem like the kind of company to chase down mammoth deals. But that doesn’t mean it won’t do just that.

Industry watchers have tabbed Alexion as a potential activist target. And one prominent activist reportedly wants to take advantage of the opportunity.

Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.